Showing 3,921 - 3,940 results of 4,407 for search '"pharmaceutical"', query time: 0.07s Refine Results
  1. 3921
  2. 3922

    Rapid Geographical Origin Identification and Quality Assessment of Angelicae Sinensis Radix by FT-NIR Spectroscopy by Zhen-yu Zhang, Ying-jun Wang, Hui Yan, Xiang-wei Chang, Gui-sheng Zhou, Lei Zhu, Pei Liu, Sheng Guo, Tina T. X. Dong, Jin-ao Duan

    Published 2021-01-01
    “…This study might serve as a reference for quality evaluation of agricultural, pharmaceutical, and food products.…”
    Get full text
    Article
  3. 3923

    Green and Innovative Extraction: Phenolic Profiles and Biological Activities of Underutilized Plant Extracts Using Pulsed Electric Fields and Maceration by Noelia Pallarés, Houda Berrada, Emilia Ferrer, Wahiba Rached, José Pinela, Filipa Mandim, Tania C. S. P. Pires, Tiane C. Finimundy, Francisco J. Barba, Lillian Barros

    Published 2025-01-01
    “…These species present an untapped source of bioactive compounds with significant applications in the food and pharmaceutical industries, including the development of functional foods and additives. …”
    Get full text
    Article
  4. 3924

    Fu Tu Sheng Jin Rehabilitation Formula Mitigate Airway Inflammation, Mucus Secretion and Immune Dysfunction Induced by SARS-CoV-2 Spike Protein by Wang BH, Yu KY, Zhang XN, Sun XH, Tang LL, Shi XL

    Published 2025-01-01
    “…Bo-Han Wang,1,* Ke-Yao Yu,2,* Xiao-Na Zhang,3,* Xian-Hong Sun,2 Ling-Ling Tang,4 Xiao-Lu Shi2 1NanJing JiangNing Hospital of Chinese Medicine/Affiliated jiangning Hospital of Chinese Medicine, China Pharmaceutical University, Nanjing, Jiangsu, 210029, People’s Republic of China; 2Affiliated Hospital of Nanjing University of Chinese Medicine/ Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu, 210029, People’s Republic of China; 3Nanjing Hospital of Chinese Medicine, Nanjing, Jiangsu, 210029, People’s Republic of China; 4School of Chinese Medicine & School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiao-Lu Shi; Ling-Ling Tang, Email fsyy00721@njucm.edu.cn; 290602@njucm.edu.cnObjective: To evaluate the effects of Fu Tu Sheng Jin Rehabilitation Formula (FTSJRF) on airway inflammation, mucus secretion, and immunoreaction in a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-induced mouse model.Methods: Forty-two mice were randomly divided into seven groups: normal, D1, D3, D10, D10H, D10M and D10L, according to the days of modeling and different dosages of FTSJRF. …”
    Get full text
    Article
  5. 3925
  6. 3926

    Ultrasound investigation at examination of gastro-intestinal tract at combined trauma by A. S. Yermolov, O. A. Alekseyechkina, Ye. S. Vladimirova, G. P. Titova, V. M. Abuchina

    Published 2015-07-01
    “…In 2 of 6 patients with intestinal trauma after suture application pharmaceutical therapy resulted in resolution of intestinal paresis. …”
    Get full text
    Article
  7. 3927
  8. 3928
  9. 3929

    PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1 by Fei Xie, Han Zhang, Kongkai Zhu, Cheng‐Shi Jiang, Xiaoya Zhang, Hongkai Chang, Yaya Qiao, Mingming Sun, Jiyan Wang, Mukuo Wang, Junzhen Tan, Tao Wang, Lianmei Zhao, Yuan Zhang, Jianping Lin, Chunze Zhang, Shuangping Liu, Jianguo Zhao, Cheng Luo, Shuai Zhang, Changliang Shan

    Published 2023-04-01
    “…Here, we report that PRMT5 is highly expressed and correlates with poor survival in ovarian cancer. Knockdown or pharmaceutical inhibition of PRMT5 is sufficient to decrease glycolysis flux, attenuate tumor growth, and enhance the antitumor effect of Taxol. …”
    Get full text
    Article
  10. 3930
  11. 3931
  12. 3932
  13. 3933
  14. 3934
  15. 3935
  16. 3936

    Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity by Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser

    Published 2025-02-01
    “…The current United States Food and Drug Administration (FDA) approved pharmaceutical therapy choices for long-term use include a combination of phentermine-topiramate, combination bupropion-naltrexone, orlistat, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dual action GLP-1RAs and gastric inhibitory peptide agonists (GIP). …”
    Get full text
    Article
  17. 3937
  18. 3938
  19. 3939
  20. 3940